France’s government may soon be held accountable for the continuous delays to the rollout of its permanent national medical cannabis framework, as pressure builds to finalise implementation.
On November 16, the Senate ordered the government to justify why the now three-year-old framework is yet to have reached a single patient, overriding its own social affairs committee to demand a firm timetable for the final texts that remain unpublished.
Senators adopted the amendment to the 2027 Social Security Financing Bill (PLFSS) last week, requiring ministers to report to Parliament on the state of Article 78 of the December 2023 law that created a permanent framework for cannabis-based medicines.
Said report must set out the texts still to be published and their expected dates, the cost of the delays to patients and the sector, and the timetable for restarting the Haute Autorité de Santé (HAS) reimbursement evaluation.
Health Minister Stéphanie Rist told senators she hoped to refer the decree governing HAS evaluation and reimbursement to the Conseil d’État in January 2027. That text was already sent for review at the start of July, no explanation of what happened to this version has yet been given.

The amendment was tabled by Socialist senator Marion Canalès and co-signed by 23 colleagues. “It is no longer a report that is needed, it is a real wake-up call,” she said.
Two decrees have held up the rollout. The first, covering product authorisation by the Agence nationale de sécurité du médicament (ANSM) and accompanied by orders on specifications and cultivation, cleared Conseil d’État review and European notification but has sat unpublished since 2025.
The government has said it will appear in the Journal Officiel alongside the second, reimbursement text. Until both are published, the HAS Transparency Commission cannot open the evaluation sessions that set benefit ratings and, with them, reimbursement levels. Hearings scheduled for October 20 and 21 were cancelled for that reason.
No new patient has joined the programme since March 2024. Around 700 remain on transitional access, due to expire at the end of December.
Industry body UIVEC, which pushed the amendment alongside the patient association APAISER, wants the government to act without waiting for the report. It has called for it to publish the three notified texts at once, and send the reimbursement decree back to the Conseil d’État now rather than in January.
Zoé Demange, UIVEC’s General Delegate, said the Senate had stated plainly what patients and clinicians had observed for three years, that the law is passed but not applied.
France had been working towards first prescriptions under the permanent framework from early 2027. With the key decree now unlikely to reach the Conseil d’État before January, and no publication date set, that window is already under strain.






